COVID Rapid Antigen Test Distributed By Virax Gets Emergency Use Authorization in US

 Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today that their supplier has received an Emergency Use Authorization ("EUA") from the U.S. FDA for their Over-the-Counter COVID-19 Rapid Antigen Test (the "Test"). The Tests are ready for sale in the US by Virax. Additionally, another Point of Care Rapid Antigen test to be distributed by Virax is seeking an approval with Health Canada for Canadian distribution. The Tests have been eligible for sale in markets accepting the CE Mark since 2020.   

https://www.biospace.com/article/releases/covid-19-rapid-antigen-test-distributed-by-virax-biolabs-receives-emergency-use-authorization-in-the-united-states/